Radiotherapy dosing for locally advanced non-small cell lung carcinoma: "MTD" or "ALARA"?

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Locally advanced non-small cell lung cancer (LA-NSCLC) is typically treated with thoracic radiotherapy, often in combination with cytotoxic chemotherapy. Despite tremendous advances in the evaluation, treatment techniques, and supportive care measures provided to LA-NSCLC patients, local disease progression and distant metastases frequently develop following definitive therapy. A recent landmark randomized trial demonstrated that radiotherapy dose escalation may reduce survival rates, highlighting our poor understanding of the effects of thoracic radiotherapy for LA-NSCLC. Here, we present rationale for further studies of radiotherapy dose escalation as well as arguments for exploring relatively low radiotherapy doses for LA-NSCLC.

Original languageEnglish (US)
Article number205
JournalFrontiers in Oncology
Issue numberSEP
StatePublished - Sep 21 2017


  • Chemoradiotherapy
  • Dose-response relationship
  • Locally advanced NSCLC
  • Lung cancer
  • Radiation
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Radiotherapy dosing for locally advanced non-small cell lung carcinoma: "MTD" or "ALARA"?'. Together they form a unique fingerprint.

Cite this